-
Mashup Score: 51Concept, Design, and Preclinical Testing of a Remote-Control Robotic System for Transesophageal Echocardiography - 2 month(s) ago
Interventional echocardiography (IE) plays a critical role in guiding structural heart interventions. IE specialists face challenges including high radiation exposure and unfavorable ergonomics. To address these issues, a novel remote-control robotic (RCR) system for transesophageal echocardiography (TEE) control has been developed. This study aims to describe the novel RCR system and to assess its performance in bench tests and in vitro models in terms of functionality, image quality, and reproducibility.
Source: www.structuralheartjournal.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5The Cost of Waiting for a Transcatheter Aortic Valve Replacement in Medicare Beneficiaries With Severe Aortic Stenosis - 7 month(s) ago
Aortic stenosis (AS) is a prevalent valvular disorder necessitating timely intervention, particularly when symptomatic. Aortic valve replacement (AVR) is the recommended treatment, but delays in access to AVR are common and linked to adverse outcomes and increased health care costs. This study aims to assess the health care cost burden associated with delaying transcatheter AVR (TAVR) in Medicare Advantage beneficiaries with clinically significant AS.
Source: www.structuralheartjournal.orgCategories: General Medicine News, CardiologistsTweet-
RT @AnkurSethi2021: https://t.co/OSQglHmDOd Delay in AS treatment can be deadly and definitely costly @RWJUH @97mjr has innovative one sto…
-
-
Mashup Score: 6The Cost of Waiting for a Transcatheter Aortic Valve Replacement in Medicare Beneficiaries With Severe Aortic Stenosis - 7 month(s) ago
Aortic stenosis (AS) is a prevalent valvular disorder necessitating timely intervention, particularly when symptomatic. Aortic valve replacement (AVR) is the recommended treatment, but delays in access to AVR are common and linked to adverse outcomes and increased health care costs. This study aims to assess the health care cost burden associated with delaying transcatheter AVR (TAVR) in Medicare Advantage beneficiaries with clinically significant AS.
Source: www.structuralheartjournal.orgCategories: General Medicine News, CardiologistsTweet-
RT @AnkurSethi2021: https://t.co/OSQglHmDOd Delay in AS treatment can be deadly and definitely costly @RWJUH @97mjr has innovative one sto…
-
-
Mashup Score: 7Characteristics and Outcomes of Patients Ineligible for Tricuspid Transcatheter Edge-to-Edge Repair - 10 month(s) ago
Tricuspid transcatheter edge-to-edge repair (T-TEER) has emerged as a safe and effective therapy for patients with severe tricuspid regurgitation (TR).1 In The Trial to Evaluate Cardiovascular Outcomes in Patients Treated with the Tricuspid Valve Repair System (TRILUMINATE), T-TEER reduced TR severity and improved quality of life.1 Severe TR is associated with an increased risk of mortality and morbidity secondary to right ventricle (RV) failure and venous congestion.2 Despite T-TEER being an appealing therapy for patients with severe TR, not all patients screened are suitable candidates for T-TEER.
Source: www.structuralheartjournal.orgCategories: General Medicine News, CardiologistsTweet-
@OKhaliqueMD @purviparwani @djc795 @CathElectroSurg @ziadalinyc @onco_cardiology And tricuspid too!! https://t.co/HACUte7Epa
-
-
Mashup Score: 7Characteristics and Outcomes of Patients Ineligible for Transcatheter Mitral Valve Replacement - 10 month(s) ago
Mitral transcatheter edge-to-edge repair (TEER) has proven to be a safe and effective treatment option in patients with primary mitral regurgitation (MR) at high or prohibitive surgical risk or those with secondary MR who remain symptomatic despite guideline-directed medical therapy (GDMT) and have favorable anatomy.1 Transcatheter mitral valve replacement (TMVR) is emerging as an important therapy for patients with symptomatic severe primary or secondary MR who are deemed high surgical risk and have unfavorable anatomy for TEER.
Source: www.structuralheartjournal.orgCategories: General Medicine News, CardiologistsTweet-
@Hragy Prevention is key. LVOTO risk is the main reason vast majority of patients are not TMVR candidates. TEER very effective and safe in appropriate FMR and DMR patients. We found >80% screen fail rate for TMVR https://t.co/IXgTwK0l99
-
-
Mashup Score: 7Characteristics and Outcomes of Patients Ineligible for Transcatheter Mitral Valve Replacement - 12 month(s) ago
Mitral transcatheter edge-to-edge repair (TEER) has proven to be a safe and effective treatment option in patients with primary mitral regurgitation (MR) at high or prohibitive surgical risk or those with secondary MR who remain symptomatic despite guideline-directed medical therapy (GDMT) and have favorable anatomy.1 Transcatheter mitral valve replacement (TMVR) is emerging as an important therapy for patients with symptomatic severe primary or secondary MR who are deemed high surgical risk and have unfavorable anatomy for TEER.
Source: www.structuralheartjournal.orgCategories: General Medicine News, CardiologistsTweet-
@Hragy Prevention is key. LVOTO risk is the main reason vast majority of patients are not TMVR candidates. TEER very effective and safe in appropriate FMR and DMR patients. We found >80% screen fail rate for TMVR https://t.co/IXgTwK0l99
-
-
Mashup Score: 1
Considerable evidence exists that heart valve disease often is unrecognized and, even when diagnosed, is undertreated. The OxValve study found that 5% of randomly surveyed Europeans had evidence of moderate to severe valve disease.1 Another study found that many elderly patients were not referred for intervention even when meeting guideline criteria for such procedures.2 Accordingly, there exists a real need for a greater awareness of the prevalence and availability of therapy for valve disease among both patients and physicians.
Source: www.structuralheartjournal.orgCategories: General Medicine News, Cardiologists1Tweet-
https://t.co/S680EDwgNF
-
-
Mashup Score: 2
Considerable evidence exists that heart valve disease often is unrecognized and, even when diagnosed, is undertreated. The OxValve study found that 5% of randomly surveyed Europeans had evidence of moderate to severe valve disease.1 Another study found that many elderly patients were not referred for intervention even when meeting guideline criteria for such procedures.2 Accordingly, there exists a real need for a greater awareness of the prevalence and availability of therapy for valve disease among both patients and physicians.
Source: www.structuralheartjournal.orgCategories: General Medicine News, Cardiologists1Tweet-
https://t.co/S680EDwgNF
-
Remote-Controlled #Robotic #TEE #echofirst by ROB'E GmbH for https://t.co/v0a6PJg2JG Safe ( esophagus no lesions Performs well Feasible Consistent(75% reproducibility in first 5 cases) #TCT2024 https://t.co/amJtp4t4W1